| Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer KL Thu, J Silvester, MJ Elliott, W Ba-Alawi, MH Duncan, AC Elia, AS Mer, ... Proceedings of the National Academy of Sciences 115 (7), E1570-E1577, 2018 | 71 | 2018 |
| Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids E Prince, J Cruickshank, W Ba-Alawi, K Hodgson, J Haight, C Tobin, ... Nature communications 13 (1), 1466, 2022 | 58 | 2022 |
| The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER+ breast cancer with mitotic aberrations I Soria-Bretones, KL Thu, J Silvester, J Cruickshank, S El Ghamrasni, ... Science Advances 8 (36), eabq4293, 2022 | 20 | 2022 |
| Development of novel agents for the treatment of early estrogen receptor positive breast cancer MJ Elliott, DW Cescon The Breast 62, S34-S42, 2022 | 12 | 2022 |
| Current treatment and future trends of immunotherapy in breast cancer MJ Elliott, B Wilson, DW Cescon Current Cancer Drug Targets 22 (8), 667-677, 2022 | 9 | 2022 |
| The antiarrhythmic drug, dronedarone, demonstrates cytotoxic effects in breast cancer independent of thyroid hormone receptor Alpha 1 (THRα1) antagonism MJ Elliott, KJ Jerzak, JG Cockburn, Z Safikhani, WD Gwynne, JA Hassell, ... Scientific Reports 8 (1), 16562, 2018 | 9 | 2018 |
| Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study MJ Elliott, M Ennis, KI Pritchard, C Townsley, D Warr, C Elser, E Amir, ... NPJ breast cancer 6 (1), 22, 2020 | 8 | 2020 |
| Cyclin-like proteins tip regenerative balance in the liver to favour cancer formation BA Fifield, J Talia, C Stoyanovich, MJ Elliott, MK Bakht, A Basilious, ... Carcinogenesis 41 (6), 850-862, 2020 | 5 | 2020 |
| Resource stratified guidelines for cancer: Are they all the same? Interguideline concordance for systemic treatment recommendations BE Wilson, MJ Elliott, SA Pearson, E Amir, MB Barton International Journal of Cancer 150 (1), 91-99, 2022 | 4 | 2022 |
| Abstract P6-01-16: Circulating Tumour DNA (ctDNA) Detection and Dynamics in Patients with Early Breast Cancer (EBC): Results of the Neoadjuvant TRACER cohort MJ Elliott, Z Veitch, P Bedard, E Amir, A Dou, JF Antras, M Nadler, N Meti, ... Cancer Research 83 (5_Supplement), P6-01-16-P6-01-16, 2023 | 2 | 2023 |
| Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer C Kappel, MJ Elliott, V Kumar, MB Nadler, A Desnoyers, E Amir Scientific Reports 14 (1), 3129, 2024 | 1 | 2024 |
| Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages H Kim, K Aliar, P Tharmapalan, CW McCloskey, A Kuttanamkuzhi, ... Cell reports 42 (10), 2023 | 1 | 2023 |
| Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 … J Fuentes Antrás, S El Ghamrasni, J Zou, A Dou, MJ Elliott, L Avery, ... Journal of Clinical Oncology 41 (16_suppl), 1075-1075, 2023 | 1 | 2023 |
| Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer N Cheng, K Skead, A Singhawansa, TW Ouellette, M Elliott, DW Cescon, ... medRxiv, 2023.01. 30.23285027, 2023 | 1 | 2023 |
| Real-world outcomes of patients with human epidermal growth factor 2 (HER2)–positive breast cancer receiving neoadjuvant therapy without adjuvant ado-trastuzumab emtansine (T-DM1). M Di Iorio, MJ Elliott, JL Scott, A Mittal, C Molto, F Tamimi, DW Cescon, ... Journal of Clinical Oncology 40 (16_suppl), 584-584, 2022 | 1 | 2022 |
| 1298P PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy SC Lau, MJ Elliott, A Rabinovitch, M Makarem, S Kuang, S Schmid, ... Annals of Oncology 32, S1005-S1006, 2021 | 1 | 2021 |
| Abstract PS06-08: Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the … M Elliott, JF Antras, P Echelard, A Dou, Z Veitch, P Bedard, E Amir, ... Cancer Research 84 (9_Supplement), PS06-08-PS06-08, 2024 | | 2024 |
| 57P Intrinsic and acquired blood-based tumor mutational burden in metastatic ER+/HER2-breast cancer treated with endocrine therapy and a CDK4/6-inhibitor M Elliott, JF Antras, S Main, A Dou, E Shah, E Van de Laar, ... ESMO Open 9, 2024 | | 2024 |
| Longitudinal ctDNA monitoring using a high sensitivity tumor-informed assay in patients with metastatic HR+/HER2− breast cancer receiving endocrine therapy … J Fuentes-Antras, MJ Elliott, P Echelard, A Dou, Z Veitch, PL Bedard, ... Cancer Research 84 (6_Supplement), 2429-2429, 2024 | | 2024 |
| Tumor-agnostic ctDNA monitoring in patients with metastatic HR+/HER2-breast cancer receiving first-line CDK4/6 inhibitor and endocrine therapy MJ Elliott, J Fuentes-Antrás, A Dou, N Gregorio, E Shah, EV de Laar, ... Cancer Research 84 (6_Supplement), 969-969, 2024 | | 2024 |
David W. CesconMedical Oncologist and Clinician Scientist, Princess Margaret Cancer Centre, University of TorontoVerified email at uhn.ca
